Daehan New Pharm Co. Ltd (054670) - Total Assets
Based on the latest financial reports, Daehan New Pharm Co. Ltd (054670) holds total assets worth ₩251.53 Billion KRW (≈ $170.46 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Daehan New Pharm Co. Ltd - Total Assets Trend (2014–2024)
This chart illustrates how Daehan New Pharm Co. Ltd's total assets have evolved over time, based on quarterly financial data. Also see Daehan New Pharm Co. Ltd (054670) total market value for the company's overall valuation and market capitalisation.
Daehan New Pharm Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Daehan New Pharm Co. Ltd's total assets of ₩251.53 Billion consist of 52.1% current assets and 47.9% non-current assets. Review debt load of Daehan New Pharm Co. Ltd to assess the company's total debt and financial obligations.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩29.73 Billion | 13.4% |
| Accounts Receivable | ₩34.29 Billion | 15.5% |
| Inventory | ₩37.21 Billion | 16.8% |
| Property, Plant & Equipment | ₩85.04 Billion | 38.4% |
| Intangible Assets | ₩1.12 Billion | 0.5% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Daehan New Pharm Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 054670 live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Daehan New Pharm Co. Ltd's current assets represent 52.1% of total assets in 2024, an increase from 40.2% in 2014.
- Cash Position: Cash and equivalents constituted 13.4% of total assets in 2024, up from 0.6% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2014.
- Asset Diversification: The largest asset category is property, plant & equipment at 38.4% of total assets.
Daehan New Pharm Co. Ltd Competitors by Total Assets
Key competitors of Daehan New Pharm Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
|
China | CN¥4.49 Billion |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
USA | $199.45 Million |
Daehan New Pharm Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.61 | 1.73 | 1.37 |
| Quick Ratio | 1.06 | 1.17 | 1.07 |
| Cash Ratio | 0.00 | 0.42 | 0.00 |
| Working Capital | ₩41.24 Billion | ₩47.13 Billion | ₩18.33 Billion |
Daehan New Pharm Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Daehan New Pharm Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.72 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 25.1% |
| Total Assets | ₩221.29 Billion |
| Market Capitalization | $52.98 Million USD |
Valuation Analysis
Below Book Valuation: The market values Daehan New Pharm Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Daehan New Pharm Co. Ltd's assets grew by 25.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Daehan New Pharm Co. Ltd (2014–2024)
The table below shows the annual total assets of Daehan New Pharm Co. Ltd from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩221.29 Billion ≈ $149.96 Million |
+25.07% |
| 2023-12-31 | ₩176.93 Billion ≈ $119.90 Million |
+4.47% |
| 2022-12-31 | ₩169.36 Billion ≈ $114.77 Million |
+7.43% |
| 2021-12-31 | ₩157.64 Billion ≈ $106.83 Million |
+18.46% |
| 2020-12-31 | ₩133.08 Billion ≈ $90.18 Million |
+4.04% |
| 2019-12-31 | ₩127.91 Billion ≈ $86.68 Million |
+17.63% |
| 2018-12-31 | ₩108.74 Billion ≈ $73.69 Million |
-10.74% |
| 2017-12-31 | ₩121.82 Billion ≈ $82.55 Million |
-6.81% |
| 2016-12-31 | ₩130.72 Billion ≈ $88.59 Million |
-1.44% |
| 2015-12-31 | ₩132.63 Billion ≈ $89.88 Million |
+1.66% |
| 2014-12-31 | ₩130.47 Billion ≈ $88.42 Million |
-- |
About Daehan New Pharm Co. Ltd
Daehan Nupharm Co.,Ltd. manufactures and sells pharmaceuticals and veterinary products in South Korea and internationally. It offers pharmaceuticals drugs for cardiovascular, endocrine system, neuropsychiatric, gastrointestinal, respiratory system, antipyretic, analgesic, anti-inflammatory, anti-infective, musculoskeletal, osteoporosis, anti-cancer, urogenital system, antifungal, antiviral, hormo… Read more